Le Lézard
Classified in: Health, Science and technology
Subjects: Restructuring / Recapitalization, Management Changes

Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition


SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has engaged SVB Securities to assist in reviewing strategic alternatives for the Company with the goal of maximizing shareholder value. Such alternatives may include a sale, merger, divestiture of assets, licensing or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. Neoleukin does not expect to disclose or provide an update concerning developments related to this process until the Company enters into definitive agreements or arrangements with respect to a transaction or otherwise determines that other disclosure is necessary or appropriate.

In connection with the evaluation of strategic alternatives, the Board of Directors of Neoleukin also approved a further corporate restructuring to preserve cash, including a reduction in the Company's workforce by approximately 70%. Chief Executive Officer Jonathan Drachman, M.D., will also be stepping down after a short transition. The Company expects this reduction in force to be completed during the first half of 2023.

"The work that Neoleukin has done to advance the science of de novo protein design for immunotherapeutic use, including what we believe is the first in-human clinical trial of a de novo protein, is important and impressive. However, based on the anticipated time and investment necessary to further develop the technology and potential product candidates in this challenging capital markets environment, we believe that it is appropriate to pursue other strategic options," said Todd Simpson, Chairman of the Board of Neoleukin. "It was a difficult decision to restructure our workforce as we conduct this review of strategic alternatives; however, we believe it was a prudent decision that will maximize shareholder value. We would like to thank Jonathan, the research team, and all employees who have worked on these ground-breaking advancements."

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.  For more information, please visit the Neoleukin website: www.neoleukin.com.

Contact:
Media
Julie Rathbun
206-769-9219
[email protected]



These press releases may also interest you

at 08:50
Tivic Health® Systems, Inc. , a health tech company developing and commercializing bioelectronic medicine, announced today that full enrollment has been completed in the optimization study for Tivic Health's patent pending, non-invasive vagus nerve...

at 08:46
Modern Plastic Surgery and Med Spa of Miami, the most luxurious plastic surgery clinic in the vibrant City of Doral, is proud to announce the celebration of its one-year anniversary this December. Led by renowned anesthesia provider Armando Luis, the...

at 08:46
Many businesspeople wonder how they will have enough energy to lead for the next 20 to 30 years because life feels like a marathon. "In my coaching and consulting practice, I often encounter leaders who feel they are running as fast as possible to...

at 08:44
Leading hearing care retailer HearUSA today announced the opening of a new modern hearing center in the Southeast area of Orlando at 10417 Moss Park Road, Orlando, FL 32832. The opening is part of HearUSA's initiative to expand...

at 08:41
Elevate is excited to welcome former NBA champion Lamar Odom as its new ambassador. Odom's journey is inspiring, and through this partnership, Elevate hopes to promote wellness and encourage healthier lifestyles. This collaboration is more than a...

at 08:41
As media outlets begin crafting "New Year, New You" content, Consumer Product Events (CPE) unveils its annual list of product recommendations to assist editors in curating their 2025 gift guides, product reviews, and roundups. "For over 35...



News published on and distributed by: